MAP2K7 and prostate cancer: Considering that activating mutations in the RAS/RAF/MEK/ERK signaling cascade are rare in prostate cancer [46, 47], sustained stimulation of the MAPK pathway by ERα is a potential mechanism to increase MYC expression in a subset of prostate cancers.